Beyond Gleevec: What's Next For Novartis Oncology?
Executive Summary
For Novartis, the targeted chronic myeloid leukemia drug Gleevec (imatinib) has been the backbone of its oncology portfolio. The drug's launch in 2003 catapulted Novartis into a major oncology player, and with revenues for Gleevec now approaching close to $4 billion in sales annually, the drug has evolved from what was considered to be a niche treatment into Novartis' second top-selling drug